Extended Treatment With PEG-Intron® and Rebetol® in Patients With Genotype 1 Chronic Hepatitis C and Slow Virologic Response (Study P03685)

NCT00265395 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1428

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatitis C, Chronic

Interventions

DRUG: Combination of pegylated interferon alfa-2b (PEG-Intron®) and ribavirin (Rebetol®)
DRUG: Combination of pegylated interferon alfa-2b and ribavirin

Sponsor

Merck Sharp & Dohme LLC